ArticleInternational journal of molecular sciences2017
Clinical Significance of Measuring Global Hydroxymethylation of White Blood Cell DNA in Prostate Cancer: Comparison to PSA in a Pilot Exploratory Study.
Article in International journal of molecular sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 15 citations in OpenAlex.
- DNA hydroxymethylation combined with carotid plaques as a novel biomarker for coronary atherosclerosis.Aging · 2019Trial
- Serum 8-OHdG as a Marker of Oxidative DNA Damage in Acute Exacerbations of COPD: Associations with GOLD Stage and Smoking Status-A Cross Sectional Study.Medicina (Kaunas, Lithuania) · 2026Article
- Rural-Urban and Demographic Inequalities in Dental Pathology and Diagnostic Patterns in Romanian Emergency Care: A Retrospective Tertiary Clinical Cohort Study.Healthcare (Basel, Switzerland) · 2026Article
- Inflammatory and Epigenetic Biomarkers in Prostate Disease: Current Evidence, Clinical Limitations, and Future Multimarker Strategies.Diagnostics (Basel, Switzerland) · 2026Review
- Article
- Demographic, Geographic, and Temporal Patterns of Adult Dental Emergency Presentations in Arad County, Western Romania.Healthcare (Basel, Switzerland) · 2026Article
- Lower Vitamin D During Acute Exacerbation Is Associated with Very Severe Chronic Obstructive Pulmonary Disease.Medicina (Kaunas, Lithuania) · 2025Observational
- Patterns of Meniscal Injuries in Adults Aged 35 and Older: A Retrospective Analysis of Surgical Cases.Medicina (Kaunas, Lithuania) · 2025Article
- Left vs. Right Bundle Branch Block in COVID-19 Patients: Distinct Clinical Presentations and Prognostic Implications.Journal of clinical medicine · 2025Article
- Sodium Butyrate: A Multifaceted Modulator in Colorectal Cancer Therapy.Medicina (Kaunas, Lithuania) · 2025Article
- Smoking and Health Profiles of Hypertensive Patients with COVID-19: An Exploratory Study of Key Physiological Markers.Journal of clinical medicine · 2024Article
- Methods for Detection and Mapping of Methylated and Hydroxymethylated Cytosine in DNA.Biomolecules · 2024Review
- Contribution of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 to Upper Tract Urothelial Cancer Risk in Taiwan.Life (Basel, Switzerland) · 2024Article
- Serum YKL-40 Levels in Patients with Asthma or COPD: A Pilot Study.Medicina (Kaunas, Lithuania) · 2023Article
- DNA Methylation and Hydroxymethylation in Cervical Cancer: Diagnosis, Prognosis and Treatment.Frontiers in genetics · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is the first study investigating the clinical relevance of 5-hydroxymethylcytosine (5hmC) in genomic DNA from white blood cells (WBC) in the context of prostate cancer (PCa) and other prostate pathologies. Using an enzyme-linked immunosorbent assay, we identified significantly different distributions of patients with low and elevated 5hmC content in WBC DNA across controls and patients with prostate cancer (PCa), atypical small acinar proliferation (ASAP), and benign prostatic hyperplasia (BPH). The measured values were within the normal range for most PCa patients, while the latter category was predominant for ASAP. We observed a wider heterogeneity in 5hmC content in all of the prostate pathologies analyzed when compared to the healthy age-matched controls. When compared to blood levels of prostate-specific antigen (PSA), this 5hmC-based biomarker had a lower performance in PCa detection than the use of a PSA cut-off of 2.5 nanograms per milliliter (ng/mL). Above this threshold, however, it delineated almost three quarters of PCa patients from controls and patients with other prostate pathologies. Overall, genome-wide 5hmC content of WBC DNA appears to be applicable for detecting non-cancerous prostate diseases, rather than PCa. Our results also suggest a potential clinical usefulness of complementing PSA as a PCa marker by the addition of a set of hydroxymethylation markers in the blood, but further studies are necessary to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.